PriceTargets.com logo

Conduit Pharmaceuticals - CDT Stock Price Target and Predictions

  • Consensus Rating: Strong Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 1 Strong Buy Ratings
$0.07 As of 12/20/2024 06:51 PM ET
▲ +0.0091 (13.87%)

This chart shows the closing price for CDT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Conduit Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CDT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CDT

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Conduit Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.07.

This chart shows the closing price for CDT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Strong Buy

The current consensus among 1 contributing investment analysts is to buy (strong buy) stock in Conduit Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024
  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/26/2024Berenberg BankUpgradeStrong-Buy
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.44 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Conduit Pharmaceuticals logo
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.
Read More

Today's Range

Now: $0.07
Low: $0.06
High: $0.08

50 Day Range

MA: $0.10
Low: $0.07
High: $0.13

52 Week Range

Now: $0.07
Low: $0.06
High: $5.51

Volume

18,690,658 shs

Average Volume

10,031,876 shs

Market Capitalization

$7.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.21

Frequently Asked Questions

What sell-side analysts currently cover shares of Conduit Pharmaceuticals?

The following equities research analysts have issued research reports on Conduit Pharmaceuticals in the last year: Berenberg Bank.
View the latest analyst ratings for CDT.

What is the current price target for Conduit Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Conduit Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Conduit Pharmaceuticals in the next year.
View the latest price targets for CDT.

What is the current consensus analyst rating for Conduit Pharmaceuticals?

Conduit Pharmaceuticals currently has 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Strong Buy."
View the latest ratings for CDT.

What other companies compete with Conduit Pharmaceuticals?

Other companies that are similar to Conduit Pharmaceuticals include RenovoRx, ProMIS Neurosciences, LianBio, NextCure and Forte Biosciences. Learn More about companies similar to Conduit Pharmaceuticals.

How do I contact Conduit Pharmaceuticals' investor relations team?

Conduit Pharmaceuticals' physical mailing address is 89 Nexus Way, Grand Cayman KY1-9009, Cayman Islands, . The company's listed phone number is 760-471-8536 and its investor relations email address is 0. The official website for Conduit Pharmaceuticals is www.conduitpharma.com. Learn More about contacing Conduit Pharmaceuticals investor relations.